Drawing for Serial No. 90207084

USPTO serial 90207084

Serial No. 90207084

Reviewed by CopyMark Law Group

Reg. 7324719Status 700Registered
Filing date
Status date
Registration date
Mar 12, 2024
Examiner
BENMAMAN, ALICE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 90207084?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Stacy L. Emhoff

Stacy L. Emhoff WALKER & JOCKE CO., LPA231 SOUTH BROADWAYMEDINA, OH 44256UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for monoclonal antibody therapies and treatments; Monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; Preparations and substances for medical and pharmaceutical use comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; Monoclonal antibodies for medical treatment and for diagnostics to bind or mask biological molecules in blood, serum plasma or tissue; Blood for medical purposes; Blood plasmaACTIVE—
035Business administrative services for medical referrals to medical specialists; Maintaining a registry of blood stem cell donors and bone marrow donors to facilitate bone marrow, organ, and blood stem cell transplant services for othersACTIVE—
039Arranging of passenger transportation services for patients who need treatment by medical specialistsACTIVE—
040Cryopreservation services; Cryopreservation of stem cell, bone marrow and cell products, donor blood and pharmaceutical substancesACTIVE—
042Medical research services, namely, the carrying out of and coordination of pharmacological studies for third parties to determine if a research topic is worth pursuing by conducting preparatory experiments on stem cells, monoclonal antibodies, mRNA samples and on living organs; Medical research services, namely, the carrying out of and coordination of studies for medical treatment for third parties to assess planned treatments for desired effects and unwanted side effects by conducting medical tests, conducting diagnosis, collecting anamnesis data, and monitoring individuals for wanted effects and unwanted side effects of a proposed medical treatment, all of the foregoing for medical research purposesACTIVE—
043Services of a travel agency, namely, making hotel reservations for stem cell donors, bone marrow donors and patients as a service for third partiesACTIVE—
044Physician services; Medical clinics; Oncology clinic, namely, radiation oncology services; Providing medical consultation regarding the special medical treatment needs of patients and providing medical advice regarding what medical specialists are needed for that medical treatment; medical consultation in the field of matching third party stem cell donors who are medically prepared for donating stem cells with stem cell receptors; Medical services, namely, the removal and collection of human cells from others that are sent to third parties for processing; Medical services, namely, the coordination of the stem cell donation with stem cell donors and stem cell recipients; Performing apheresis blood collection for the collection of stem cells for third partiesACTIVE—
045Providing case management services, namely, coordinating medical services for patients who need treatment by medical specialistsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 12, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 12, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 1, 2024DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Feb 1, 2024AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 5, 2023IUCNNOTICE OF ALLOWANCE CANCELLED—
Dec 5, 2023EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Aug 22, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 27, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 27, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 7, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 23, 2023PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 16, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 15, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 14, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 14, 2023ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 14, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
May 14, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 14, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 14, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 14, 2023CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 22, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 22, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2022ALIEASSIGNED TO LIE—
Oct 27, 2022ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
May 17, 2022GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
May 17, 2022GNSIINQUIRY TO SUSPENSION E-MAILED—
May 17, 2022CNSISUSPENSION INQUIRY WRITTEN—
May 13, 2022RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Sep 21, 2021GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 21, 2021GNSLLETTER OF SUSPENSION E-MAILED—
Sep 21, 2021CNSLSUSPENSION LETTER WRITTEN—
Aug 17, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 16, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 16, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 17, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2021DOCKASSIGNED TO EXAMINER—
Nov 4, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Nov 3, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 28, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance